| Abstract | This report presents the results of the 2013 14 evaluation of the National Research Council (NRC) Human Health Therapeutics (HHT) Portfolio. HHT mainly targets Canadian small and medium enterprises (SMEs) who develop therapeutics and vaccines to address unmet needs in human health. The Portfolio hosts three programs: Biologics and Subsequent Entry Biologics, Vaccines, and Therapeutics Beyond Brain Barriers (TBBB). The primary mode of interaction with these companies is the co-development of a product (therapeutic or vaccine) through R and D agreements. These co-development agreements are complemented by licensing and research services activities. Overall, these interactions are expected to de-risk the development of therapeutics and vaccines for HHT partners and accelerate the progress of candidates to clinical trials and market, thereby catalyzing the generation of wealth for industrial partners, increasing the availability of new or improved treatments and reducing health care costs. |
|---|
